A5101558918- Dialysis and Renal Disease Management
- Chronic Myeloid Leukemia Treatments
- Acute Kidney Injury Research
- Electrolyte and hormonal disorders
- Potassium and Related Disorders
- Parathyroid Disorders and Treatments
- Renal Diseases and Glomerulopathies
- Chronic Lymphocytic Leukemia Research
- Pharmacological Effects and Toxicity Studies
- Blood Pressure and Hypertension Studies
- Chronic Kidney Disease and Diabetes
- Renal function and acid-base balance
- Acute Myeloid Leukemia Research
- Erythropoietin and Anemia Treatment
- Renal and Vascular Pathologies
- Vitamin D Research Studies
- Ion Transport and Channel Regulation
- Atrial Fibrillation Management and Outcomes
- Urinary Bladder and Prostate Research
- Muscle and Compartmental Disorders
- Metabolism and Genetic Disorders
- Kidney Stones and Urolithiasis Treatments
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Hormonal Regulation and Hypertension
- Pediatric Urology and Nephrology Studies
University of Brescia
2019-2024
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2024
Federico II University Hospital
2013-2022
University of Naples Federico II
2007-2022
Hôpital Pontchaillou
2020
Catholic University of Korea
2019
Seoul St. Mary's Hospital
2019
Istituto Oncologico Veneto
2019
Vita-Salute San Raffaele University
2012-2014
University of Bologna
2011-2013
The pathophysiology and prevention of contrast media (CM)-induced nephropathy in chronic renal failure (CRF) are still ill defined. GFR, RPF, endothelin-1 (ET-1) levels, urinary sodium concentration, fractional excretion were measured CRF patients undergoing water diuresis basal conditions 20 to 120 min after an iv bolus either the high-osmolar CM diatrizoate (D) or low-osmolar iopamidol (I). two induced immediate progressive decline both GFR RPF absence hypovolemia, more pronounced D (-36%...
In a prospective, multicenter, double-blind, randomized clinical trial, we compared the efficacy of piperacillin-tazobactam (4.5 g 3 times daily intravenously) plus placebo versus amikacin (7.5 mg/kg twice for treatment 760 febrile, adult patients with cancer chemotherapy-induced profound (<500 neutrophils/mm3) and prolonged (>10 days) neutropenia. A total 733 were assessable drug regimens, an overall successful outcome was reported in 49% (179 364) who received monotherapy, 53% (196 369)...
Summary. A retrospective survey was conducted over a 10‐year period (1990–99) among 52 haematology divisions in order to evaluate the clinical and laboratory characteristics outcome of patients with proven Pneumocystis carinii pneumonia (PCP) complicating haematological diseases. The study included 55 (18 non‐Hodgkin's lymphoma, 10 acute lymphoblastic leukaemia, eight myeloid five chronic four lymphocytic multiple myeloma, three myelodysplastic syndrome, two myelofibrosis one thalassemia)...
Contrast media affect renal hemodynamics. Hyperosmolality is regarded as the major factor responsible for hemodynamic changes. In this study, role of osmolality was evaluated in 30 hospitalized patients without risk factors during intravenous pyelography. with low and high were used. addition, nifedipine administered before infusion high-osmolality contrast to evaluate calcium ions radiocontrast-induced changes Hyperosmolar reduced plasma flow glomerular filtration rate. Calcium channel...
Background People with reduced glomerular filtration rate (GFR) often have elevated cardiac troponin T (cTnT) levels. It remains unclear how cTnT levels develop over time in those chronic kidney disease (CKD). The aim of this study was to prospectively the association between and GFR older advanced‐stage CKD patients not on dialysis. Methods Results EQUAL (European Quality Study) is an observational prospective cohort stage 4 5 aged ≥65 years dialysis (incident estimated GFR, <20...
In non-dialysis chronic kidney disease (CKD), absolute proteinuria (Uprot) depends on the extent of damage and residual glomerular filtration rate (GFR). We therefore evaluated, as compared with Uprot, strength association indexed to estimated GFR (eGFR) end-stage renal (ESRD) risk.In a multi-cohort prospective study in 3957 CKD patients Stages G3-G5 referred nephrology clinics, we tested two multivariable Cox models for ESRD risk, either Uprot (g/24 h) or filtration-adjusted (F-Uprot)...
Erythropoietin has been shown to have a protective effect in certain models of ischaemia-reperfusion, and some cases the protection correlated with activation signalling pathways known play role cell survival proliferation. We studied whether erythropoietin would overcome direct toxic effects hydrogen peroxide (H(2)O(2)) treatment human renal proximal tubular (HK-2) cells.HK-2 cells were incubated H(2)O(2) (2 mm) for 2 h or without at concentrations 100 400 U/ml, viability/proliferation was...
Radiocontrast media (RCM)-induced nephrotoxicity (CIN) is a major clinical problem accounting for 12% of all hospital-acquired cases acute kidney injury (AKI). The pathophysiology AKI due to RCM not well understood, but direct toxic effects on renal cells have been postulated as contributing CIN. It believed that iso-osmolar (IOCM) are less nephrotoxic than low-osmolar (LOCM) data controversial. We investigated the intracellular signaling pathways may be affected by LOCM iomeprol (IOM) and...
The presence of pre-existing abdominal wall defect (AWD) could represent a potential contraindication for peritoneal dialysis (PD) treatment. We report the results our 6-year experience involving simultaneous repair AWD and catheter insertion PD.Patients with estimated glomerular filtration rate (e-GFR) 7-10 ml/min attending single nephrology clinic between January 2008 December 2014 were evaluated. Simultaneous placement was performed. For inguinal (IH) or umbilical hernia (UH), prolene...
Whether paricalcitol (PCT) reduces proteinuria in the presence of intensified inhibition Renin-Angiotensin-System (RAS) is poorly studied. We evaluated antiproteinuric effect PCT non-dialysis chronic kidney disease (CKD) patients with greater than 0.5 g/24 h persisting despite anti-RAS therapy titrated to minimize absence adverse effects. Forty-eight CKD were studied first six months add-on oral (1 mcg/day) and three after drug withdrawal. Males 87.5%, age 63 ± 14 yrs, systolic/diastolic...